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pneumoniaeBackground: Community-acquired pneumonia (CAP) is the leading cause of hospitalization of
children. Mycoplasma pneumoniae is one of the most common pathogens. The disease severity
is diverse, and the diagnosis remains a challenge to clinical pediatricians. The aims of this
study are to provide a nationwide surveillance of the epidemiology and clinical manifestations
of community-acquired mycoplasma pneumonia (CAMP) in children in Taiwan.
Methods: The medical records of children enrolled by the Taiwan Pediatric Infectious Disease
Alliance (TPIDA) project during 2010e2011 were reviewed. Hospitalized children with
segmental or lobar pneumonia were included. The demographic, clinical, laboratory and radio-
graphic data were analyzed. Nasopharyngeal swabs, pleural effusion, and serum were
collected for multiplex viral and bacterial polymerase chain reaction (PCR), mycoplasma
immunoglobulin M (IgM), or paired immunoglobulin G (IgG) titer.
Results: There were overall 127 children with CAMP. Among them, 16 (12.6%) children had PCR
and IgM positivity, 74 (58.3%) children had a positive serologic study, 34 (27.8%) children had
positive PCR detection, and three (2.4%) children had paired IgG above a four-fold increase.
Enrolled patients were divided into two groups before and after the age of 5 years. Children
younger than 5 years or younger had a significantly longer hospitalization, higher intensive care
unit (ICU) admission rates, and more complications. They were more frequent to receive oxy-
gen supplementation and even surgical intervention. The white blood cell counts and C-reac-
tive protein levels were higher in children 5 years old or younger.
Conclusion: Mycoplasma pneumoniae is an important etiology of CAP in children 5 years or
younger. They had a longer length of hospitalization, higher inflammatory responses, and more
complications, compared to children older than 5 years.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pneumonia is a common complication of respiratory tract
infection. For younger children, elders, and immunocom-
promised individuals, pneumonia can lead to death. Ac-
cording to World Health Organization (WHO), pneumonia
was a major cause of mortality among children in 2010.1
Pneumonia accounts for 21% of mortality in children
younger than 5 years in African and Eastern Mediterranean
regions and 12% of mortality in the Americas and in Euro-
pean regions.2 In Taiwan, pneumonia was the fifth cause of
death in children 1e14 years old in 2012.3 Community-
acquired pneumonia (CAP) is also a common cause of hos-
pitalization of children. Community-acquired pneumonia is
usually clinically classified as “typical” or “atypical”
pneumonia. Typical pneumonia is caused by bacteria and
atypical pneumonia is caused by Mycoplasma pneumoniae,
Chlamydia pneumoniae, or viruses. In previous reports, M.
pneumoniae has an important role in pediatric CAP.
M. pneumoniae is a small fastidious bacterium that lacks
a cell wall. This unique feature makes it invisible on Gram
stain, difficult to culture, and even insensitive to general
antibiotics such as the beta-lactams used to treat CAP. As a
causative pathogen of atypical pneumonia, M. pneumoniae
infection can occur at any age. School-aged children and
adolescents have the highest attack rates. Children younger
than 3 years tend to develop upper air way infection,
whereas children 5w20 years tend to develop acute bron-
chitis and pneumonia.4-6 Fever and cough are the most
common symptoms,7 but extrapulmonary manifestations
occur occasionally. The severity of M. pneumoniae infec-
tion varies from self-limited upper respiratory tractinfection to complicated pneumonia to even mortality.8
The prevalence of macrolide-resistant M. pneumoniae is
rising in Japan9 and China,10 although recent studies show
that the recent resistance rate is 12.3e23% in Taiwan.11,12
Macrolide remains the first-line drug to treat M. pneumo-
niae infection.
The “gold standard” for the diagnosis of M. pneumoniae
infection is still lacking. Single positivity of serum immu-
noglobulin M (IgM) and a four-fold or greater titer increase
in serum immunoglobulin G (IgG) are the most common
laboratory diagnostic tools. Polymerase chain reaction
(PCR) is a sensitive but time-consuming method. The cost
and technique-dependent procedure limits the use of PCR.
Prompt diagnosis of M. pneumoniae infection remains
challenging in the current era. By using radiographic find-
ings, the aims of this study are to provide nationwide sur-
veillance of the epidemiology and clinical manifestations of
community-acquired mycoplasma pneumonia (CAMP) in
hospitalized children in Taiwan.
Methods
Taiwan Pediatric Infectious Disease Alliance
Taiwan Pediatric Infectious Disease Alliance (TPIDA) is a
collaborative consortium established by nine pediatric in-
fectious disease departments of tertiary medical centers,
which include the National Taiwan University Hospital
(Taipei City, Taiwan), Mackay Memorial Hospital (Taipei
City, Taiwan), Chang Gung Memorial Hospital at Linkou
(Linkou, Taiwan), China Medical University Hospital (Tai-
chung City, Taiwan), National Cheng Kung University
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morial Hospital (Kaohsiung City, Taiwan), Buddhist Tzu Chi
General Hospital (Hualien, Taiwan). In 2010, nationwide
surveillance of childhood CAP began. The study was
approved by the Institutional Review Board in each hospi-
tal. Informed consent was obtained from each participating
patient or the patient’s parents or guardian. This study was
approved by the Institutional Review Boards of the afore-
mentioned institutions.
Enrollment criteria
Hospitalized children under 18 years who were diagnosed
from 2010 to 2011 as having CAP with radiographic evidence
in participant hospitals were prospectively enrolled. The
demographic data, clinical features, laboratory findings
and radiographic evidence were analyzed. The enrolled
children were further divided into two groups before and
after the age of 5 years.
Radiographic definitions
Chest radiographs of the enrolled patients were interpreted
by two pediatricians without knowledge of the patients’
clinical information. Based on the consensus of interpre-
tation,13 the area and distribution of the lung parenchyma
and the abnormality of the pleura were evaluated. Patients
with segmental or lobar pneumonia and complete clinical
information were included.
Case definitions
All nasopharyngeal swabs were submitted for the detection
of viral pathogens: direct fluorescent antibody testing, viral
culture, and nucleic acid tests. Multiplex PCR of the pleural
effusion was performed to identify other respiratory bac-
terial pathogens. The nucleic acid tests to detect M.
pneumoniae from nasopharyngeal samples were executed.
Serum samples were tested for the presence of antibodies
to M. pneumoniae by using the IgM-specific MycoplasmaTable 1 Demographic data and clinical characteristics of child
5 y/o
n Z 61 (%)
> 5
n Z
Age (y) 3.88  0.91 8.17
Sex (male) 26 (42.6) 32 (
School attendance 41 (67.2) 63 (
Underlying disease 3 (4.9) 1 (
Symptoms
Fever 60 (98.4) 66 (
Cough 59 (96.7) 64 (
Tachypnea 21 (34.4) 8 (
Vomiting 17 (27.9) 9 (
Abdominal pain 9 (14.8) 11 (
Diarrhea 7 (11.5) 8 (
* The p values in bold font indicate statistical significance.
CAMP Z community-acquired mycoplasma pneumonia; TPIDA Z TaiwImmuno-Card, an enzyme immunoassay by Meridian
Bioscience (Cincinnati, OH), and the Mycoplasma pneumo-
niae IgG/IgM Antibody Test System (FTI-SERODIA-myco II
test; Fujirebio Inc., Taipei, Taiwan) under the manufac-
turers’ instructions.
M. pneumoniae infection was defined by one of the
following criteria: (1) positivity of mycoplasma IgM in acute
stage, (2) positive detection of M. pneumoniae in naso-
pharyngeal swab by PCR, (3) four-fold or greater increase in
the mycoplasma IgG titer in the acute stage and convales-
cent stage. Patients with complicated pneumonia were
defined as patients who had pleural effusions, pneumato-
celes, or respiratory failure with intubation.
Statistical analysis
All statistical analysis was performed using PASW Statistic
software, version 18.0 for Windows (18.0; SPSS Inc., Chi-
cago, Illinois, USA). Parametric data were compared using
analysis of variance (ANOVA). Categorical data were
analyzed using contingency table analysis and Pearson’s
Chi-square test. Statistical significance was defined as
p < 0.05 in the tests.
Results
Clinical and radiographic findings
Between 2010 and 2011, 492 children in the TPIDA project
with segmental or lobar pneumonia were enrolled. There
were overall 128 (26.0%) children with CAMP. One patient
who was not hospitalized was excluded. Most children
with CAP were 3e10 years old. The mean age was
6.11  3.13 years and the male-to-female ratio was 1:1.2.
There were 61 children 5 years or younger and 66 children
older than 5 years (Table 1). However, M. pneumoniae had
highest the attribution to CAP in children over 5 years old
(Fig. 1). The seasonal distribution of patients with CAP
showed that the number of cases decreased in May, June,
and July (Fig. 2). In 2010, the number of CAMP casesren with CAMP in the 2010e2011 TPIDA project
y/o
66 (%)
Total
N Z 127 (%)
p
 3.03 6.11  3.13 < 0.001*
48.5) 58 (45.7) 0.593
95.5) 104 (81.9) < 0.001
1.5) 4 (3.1) 0.350
100) 126 (99.2) 0.480
97.0) 123 (96.9) > 0.99
12.1) 29 (22.8) 0.003
13.6) 26 (20.5) 0.005
16.7) 20 (15.7) 0.799
12.1) 15 (11.8) 0.781
an Pediatric Infectious Disease Alliance; y/o Z years old.
Figure 1. Age distribution of patients with CAMP and the
ratio of CAMP to CAP in the 2010e2011 TPIDA project.
CAMP Z community-acquired mycoplasma pneumonia;
CAP Z community-acquired pneumonia; TPIDA Z Taiwan Pe-
diatric Infectious Disease Alliance.
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pneumoniae infection was approximately 20e40% of CAP
cases. Among them, 16 (12.6%) patients had both PCR and
IgM positivity, 74 (58.3%) patients had positive serologic
study, 34 (27.8%) patients had positive PCR detection, and
3 (2.4%) patients had paired IgG titer with a four-fold or
greater increase.
Among the patients, 81.9% of them attended school
(95.5% of the children were older than 5 years and 67.2% of
the children were 5 years or younger, p < 0.001). Four
children had underlying disease, which included two chil-
dren 5 years or younger with neurologic diseases, one child
with asthma, and one child older than 5 years with atrial
septal defect status post operation. The most common
symptoms in all children were fever (99.2%) and cough
(96.9%). Tachypnea and vomiting were significantly higher
in children 5 years or younger (p < 0.05). The right and left
lower lungs were overall the most common involved areas
(Fig. 3). The location of the major lesion of pneumonia was
not statistically different in both age groups. One-half of
the children had lobar pneumonia in both groups.Figure 2. The number of patients with CAP and the ratio
CAMP Z community-acquired mycoplasma pneumonia; CAP Z comClinical course and laboratory findings
M. pneumoniae was the single pathogen identified in 75.4%
of children 5 years or younger and in 83.3% of children older
than 5 years. Codetection of bacteria and virus were
observed in both groups (Table 2). Seven children 5 years or
younger and one child older than 5 years had bacteria
codetection, which were all Streptococcus pneumoniae.
Adenovirus and rhinovirus were the most common code-
tected viruses in both groups. The mean duration of fever
was 8.34  4.50 days and there was no statistical difference
in either age group (Table 3). The duration of hospitaliza-
tion was significantly longer in children 5 years or younger
(p < 0.001), and the need for intensive care unit (ICU)
admission and oxygen supplement were also significantly
higher (p < 0.05). In total, 6 (9.8%) children 5 years or
younger received ventilator support and 9 (14.8%) children
received video-assisted thoracoscopic surgery (VATS).
Among children who underwent surgery, 5 of them had S.
pneumoniae in the pleural effusion (4 infections were
serotype 19A, 1 infection was serotype 3). None of the
children older than 5 years received surgery, and only one
child was intubated. In total, 60.6% patients received
macrolide, which included 52.5% of children 5 years or
younger and 68.2% of children older than 5 years. No sig-
nificant difference in macrolide prescription was observed.
The highest white blood cell counts (10,649  5342/mm3 vs.
16,387  10,840/mm3, p < 0.05) and the C-reaction protein
levels (8.68  9.19 mg/dL vs. 14.00  12.10 mg/dL,
p < 0.05) were significantly higher in children 5 years or
younger.
In total, 33 children had complicated pneumonia, which
included 24 children 5 years or younger and nine children
older than 5 years. Children 5 years or younger had a
significantly higher rate of complicated pneumonia (39.3%
vs. 13.6%, p < 0.05). Most children with complicated
pneumonia presented with pleural effusion (30/33, 90.9%);
21.2% of children had respiratory failure, and 6.1% of chil-
dren had pneumatoceles. Only 14 (42.4%) of them received
macrolide. Compared to children without complications,of CAMP to CAP, according to the month of the year.
munity-acquired pneumonia.
Figure 3. The chest radiographic presentation of children with community-acquired mycoplasma pneumonia. LLL Z left lower
lobe; LUL Z left upper lobe; PN Z pneumonia; RLL Z right lower lobe; RML Z right middle lobe; RUL Z right upper lobe.
Table 3 The clinical course and laboratory data of chil-
dren with CAMP
 5 y/o
n Z 61 (%)
> 5 y/o
n Z 66 (%)
p
Clinical course
Duration of
fever (d)
8.77  5.14 7.94  3.81 0.549
Hospitalization
(d)
10.87  9.20 6.29  4.56 < 0.001*
ICU admission 20 (32.8) 8 (12.1) 0.006
O2 requirement 29 (47.5) 19 (28.8) 0.016
Ventilation use 6 (9.8) 1 (1.5) 0.053
VATS 9 (14.8)a 0 (0) 0.001
Macrolide use 32 (52.5) 45 (68.2) 0.202
636 Y.-J. Ma et al.these children had a significantly lower rate of macrolide
treatment (p < 0.05).
Discussion
Community-acquired pneumonia is a common pediatric
disease worldwide. The disease severity varies by etiology,
age and host immunity. Thus, pediatric CAP shows a di-
versity in epidemiology and clinical manifestations in
different countries. Among the hospitalized children with
CAP, 79e85.6% had at least one identified pathogen.14e16
The incidence of M. pneumoniae infection ranged
7e37%.14,15 Prospective, single-hospital based studies
demonstrate that at least one pathogen was detected in
79% of hospitalized children with CAP, which includes 26%
of M. pneumoniae, 11% of C. pneumoniae, and 19% of vi-
ruses.15,16 An analysis study in Singapore identified patho-
gens in 38.4% of children, which include typical bacteria in
10.3% of infections, M. pneumoniae in 20.3% of infections,
and viruses in 5.5% of infections.17 A local surveillance
study can provide more useful information for clinicians. InTable 2 Codetection of pathogens in children with CAMP
 5 y/o
n Z 61 (%)
> 5 y/o
n Z 66 (%)
M. pneumoniae 46 (75.4) 55 (83.3)
M. pneumoniae þ bacteria 7 (11.5)a 1 (2.3)c
M. pneumoniae þ virus 9 (14.8)b 10 (15.2)d
a All infections were Streptococcus pneumoniae.
b Four infections were adenovirus, and three infections were
rhinovirus.
c The infections were Streptococcus pneumoniae.
d Five infections were adenovirus and two infections were
rhinovirus.
CAMP Z community-acquired mycoplasma pneumonia;
M. pneumoniae Z Mycoplasma pneumoniae; y/o Z years old.northern Taiwan, a prospective study demonstrated that S.
pneumoniae, M. pneumoniae, and viruses accounted for
42%, 37%, and 41%, respectively, of hospitalized children
with CAP.14 Codetection was common in the current study.Laboratory data
Highest WBC
(/mm3)
16387  10840 10649  5342 0.001
Highest CRP
(mg/dL)
14.00  12.10 8.68  9.19 0.018
Complications 24 (39.3) 9 (13.6) 0.001
Pleural effusion 21 (34.4) 9 (13.6) 0.545
Pneumatocele 2 (3.3) 0 0.229
Respiratory
failure
6 (9.8) 1 (1.5) 0.642
a Five of the patients had S. pneumoniae in the pleural
effusion.
* The p values in bold font indicate statistical significance.
CAMP Z community-acquired mycoplasma pneumonia;
CRP Z C-reactive protein; ICU Z intensive care unit;
O2 Z oxygen; VATS Z video-assisted thoracoscopic surgery;
WBC Z white blood cell; y/o Z years old.
Pediatric community-acquired mycoplasma pneumonia 637The prevalence of CAMP was 26.0% in hospitalized children,
which was similar to the findings in previous reports.
However, children 5 years or younger accounted for nearly
one-half (48%) of children with CAMP, and they had a more
complicated clinical course and outcome. Some studies
report that the prevalence of children 5 years or younger
with CAMP was approximately 46.5e61.5%.18,19 Korppi
et al20 also observed that children younger than 4 years had
a higher hospitalization rate with CAMP in comparison to
children older than 5 years (67% vs. 4%, respectively).
However, the studies had some inconsistencies because of
the heterogeneity in case definition. Most studies only
enrolled hospitalized children, and thus other children
having CAMP with mild symptoms may be missed. Another
limitation of meta-analysis is the variability of diagnostic
tools in each study. Methods that were used to detect M.
pneumoniae infection included culture, complement fixa-
tion, serologic testing, and molecular-based detection as-
says.21,22 There is still no single “gold standard” for
diagnosis. The most convenient diagnostic method are
commercial serologic testing kits such as enzyme immuno-
assay and indirect immunofluorescence.21,22 However, the
serologic testing depends on the change between two
consecutive serum IgG titers, which can only provide evi-
dence of recent infection retrospectively. Single serum IgM
positivity can be used to prove acute M. pneumoniae
infection, but IgM can only be detected 1e2 weeks after
infection. The development of PCR may overcome the
limitation of serologic tests and provide sensitive evidence
in acute infection.23 During the community outbreaks of
CAMP, Thurman et al21 found decreased sensitivity of PCR
with increased interval between symptom onset and spec-
imen collection; however, the serologic assays have an
opposite trend. Many studies have been conducted to
compare serologic testing and PCR for the diagnosis of M.
pneumoniae infection, and a great discrepancy between
these two methods has been observed.24,25 A large retro-
spective study, which investigated more than 10,000 hos-
pitalized children with M. pneumoniae infection, found a
higher discrepancy rate in the results between PCR and IgM
tests in children younger than 3 years. They suggest that
PCR is the preferred method for M. pneumoniae diagnosis in
younger children because of their immature immune
response to M. pneumoniae infection.25 Although the
advantage of PCR is its high sensitivity, the result of PCR
cannot be used to differentiate the asymptomatic carriage
of M. pneumoniae in upper respiratory tract from true
infection.26 A combination of M. pneumoniae molecular
and serologic methods may be the most suitable way to
diagnose M. pneumoniae infection. A single positive result
may not be a strong indicator for diagnosis.
Our study showed twoethirds of children 5 years or
younger attended kindergarten. The school attendance
rate may be variable in different socioeconomic cultures.
One hypothesis is that the younger age of school atten-
dance may contribute to a higher carriage rate of M.
pneumoniae and lead to higher risk of M. pneumoniae
infection. Therefore, general surveillance of the carriage
rate of M. pneumoniae in the general population is needed.
In this study, children with complicated pneumonia had a
lower rate of a prescription for macrolide. M. pneumoniae
infection may be a self-limited disease in most condition,although prompt treatment can decrease the rate of
complications.
The current study represented the presentations of
hospitalized children with CAMP in Taiwan from 2010 to
2011 by the TPIDA project.
This study has some limitations. First, selection bias is
unpreventable, especially in a multicenter study. In addi-
tion, younger children with CAP had greater tendency for
hospitalization, compared to school-aged children. Second,
only our own inclusion criteria was defined and failed to
establish the consistency of M. pneumoniae infection. This
limitation also exists in other studies of M. pneumoniae
infection, which results in a difficulty in comparing the
results. Third, each hospital may have different tools to
diagnose M. pneumoniae infection. The PCR of M. pneu-
moniae was performed in a central laboratory, whereas the
serology tests were performed in each hospital. The dif-
ferences in sensitivity and specificity may cause selection
bias. Fourth, codetection, coinfection, or contamination of
coexisting pathogens was not well defined, which is also a
common limitation in other studies of pneumonia in
children.
In conclusion, M. pneumoniae remains an important
pathogen in pediatric CAP. M. pneumoniae had a
higher attribution in children older than 5 years with CAP,
although children younger than 5 years with CAMP had a
more complicated clinical course and higher inflammatory
responses. Definite diagnosis may depend on the
application of the molecular and serologic techniques.
Further surveillance studies are needed to explore the
carriage rate of M. pneumoniae in the general population in
the community.
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